Департамент клинических исследований

Департамент клинических исследований

Clinical trials department

Slider

Hours worked

17500 +

Protocols involved

20 +

Sponsors secured

10 +

Why pharmaceutical companies choose us?

Time efficiency

at all clinical trial stages

Professionalism

of the investigators and study coordinators team

Extensive experience

in conducting clinical trials

Specialization

of the department in clinical trials

Our approach

Four simple steps for a successful clinical trial start
Clinical trial feasibility study
Ethics assessment
Patient enrollment channels evaluation
Step-by-step trial planning

Our resources

We are all set for conducting top notch clinical trials

Referral sites

Referral sites network includes policlinics and hospitals

Local Ethics Committee

Meeting 2 times per month or as needed

Investigators team

A wide range of therapeutic areas

Patients home visits service

Home visitation services for patients are conducted strictly in line with industry standards

Modern equipment

Fully equipped study site

Subjects pool

Potential patients pool proprietary constantly updated database of over 20000 potential participants

"Big Pharma" trust us

If you are interested in a reliable partner for conducting top notch phase II-III clinical trials on a wide range of nosologies and still do not work with us, please contact us

News

Stay up to date
Opening of the center: biological therapy of rheumatoid arthritis

We invite patients with seropositive rheumatoid arthritis of moderate or high degree of disease activity and insufficient response to methotrexate monotherapy to participate in a clinical trial of a new form of tocilizumab

Opening of the Site: HIB-vaccine for children from 3 to 6 months

Recruitment for a clinical trial of a new Russian HIB vaccine for children from 3 to 6 months has begun. The comparison drug is Pentaxime, the placebo group is not assumed. All examination and supervision of a pediatrician is free of charge.

Selection of the Site: a study on the treatment of patients with gastroesophageal reflux disease

Successfully passed a selection visit to participate in a clinical research of a new medicine for the treatment of erosive form of gastroesophageal reflux disease

Our partners

Protagonist
Gilead
Mithra
PRA Health Sciences
Pfizer
Rusmo-AG
Sanofi
Abbvie
Icon
Astra Zeneca
Gedeon Richter
Cromos Pharma
PPD
X7 Research
Synteract
IQVIA
Biorasi | Built for Faster Clinical Trials
PSI
ALK
Galecto
SRG
Clinipas
Astellas
Janssen
JonsonAndJonson
OCT
Celgen
Bristol-Myers Squibb Company
Biogen